Stockscreener 앱 받기
2.32
0.00%
0.00
시간 외 거래:
2.31
-0.010
-0.43%
전일 마감가:
$2.32
열려 있는:
$2.32
하루 거래량:
1.68M
Relative Volume:
0.52
시가총액:
$1.03B
수익:
$69.64M
순이익/손실:
$-26.09M
주가수익비율:
-32.45
EPS:
-0.0715
순현금흐름:
$-38.80M
1주 성능:
-0.85%
1개월 성능:
+1.31%
6개월 성능:
+56.76%
1년 성능:
+94.96%
1일 변동 폭
$2.295
$2.35
1주일 범위
$2.17
$2.475
52주 변동 폭
$1.03
$2.68
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
2.32 | 970.00M | 69.64M | -26.09M | -38.80M | -0.0715 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st
Lexicon (LXRX) Levels: Slides 0.41% to $2.41 in the Current Update; Technical Setup - vinanet.vn
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals Inc (LXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart - ChartMill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
LEXICON PHARMACEUTICALS, INC. SEC Filing (Aug 17, 2026) - Stock Titan
LXRX|Lexicon Pharmaceuticals Inc|Price:2.335|Chg%:+0.015 - TradingKey
Lexicon Pharmaceuticals (LXRX) Trading Near $2.34: Support and Resistance Define Near-Term RangeGamma Squeeze - vinanet.vn
Is Lexicon’s Earnings Slide And New Share Shelf Altering The Investment Case For Lexicon Pharmaceuticals (LXRX)? - simplywall.st
Lexicon Pharmaceuticals (STU:LX31) EV-to-OCF : -14.01 (As of Aug. 15, 2026) - GuruFocus
Analysts Have Made A Financial Statement On Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Second-Quarter Report - simplywall.st
Lexicon Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-08-10 - Seeking Alpha
Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat
HC Wainwright Issues Positive Forecast for LXRX Earnings - MarketBeat
Lexicon Pharmaceuticals, Inc. (LXRX) stock price, news, quote and history - Yahoo Finance UK
Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexicon Pharmaceuticals (LXRX) Stockholders Plan to Sell 1.26M S - GuruFocus
Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highl - GuruFocus
Lexicon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $3.86, Implies 57% Upside - TradingView
Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ... - Yahoo Finance
Lexicon Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Lexicon Pharmaceuticals (Nasdaq: LXRX) files shelf to register 1.26M warrant shares - Stock Titan
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - moomoo.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down on Disappointing Earnings - MarketBeat
FMR LLC (LXRX) discloses 11.7% Lexicon Pharmaceuticals stake in amended 13G - Stock Titan
Is Lexicon Pharmaceuticals (LXRX) Facing Challenges After Q2 Ear - GuruFocus
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Lexicon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss - marketscreener.com
Earnings Flash (LXRX) Lexicon Pharmaceuticals, Inc. Reports Q2 Revenue $692,000, vs. FactSet Est of $4.0M - marketscreener.com
Lexicon: Q2 Earnings Snapshot - marketscreener.com
Lexicon Pharmaceuticals posts Q2 net loss - TradingView
Lexicon Pharmaceuticals Q2 revenue falls to $0.7 million amid clinical updates - Quiver Quantitative
Lexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA Resubmission - Quiver Quantitative
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - The Manila Times
Lexicon Pharma (Nasdaq: LXRX) swings to $31.8M Q2 2026 loss - Stock Titan
BRIEF-Lexicon Pharmaceuticals Q2 EPS USD -0.07 - TradingView
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Zacks Research - MarketBeat
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Lexicon Pharmaceuticals (LXRX) Slips 1.28% as Shares Hold Above Key SupportLiquidity Order Flow - dars.gov.et
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
Lexicon schedules Aug. 6 call and webcast for Q2 results - Stock Titan
Lexicon Pharmaceuticals (LXRX) to Release Earnings on Wednesday - MarketBeat
Lexicon Pharmaceuticals (LXRX) Rallies 4.93% as Biotech Stock Tests Key Resistance at $2.46Volume Gap - vinanet.vn
Lexicon (LXRX) Completes Patient Randomization in Key Phase 3 Tr - GuruFocus
Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment - marketscreener.com
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):